scholarly journals Impact of hepatitis B vaccine in Tunisia 20 years after its introduction

2019 ◽  
Vol 29 (Supplement_4) ◽  
Author(s):  
A Lahchaichi ◽  
M Ben Hadj ◽  
H Bouguerra ◽  
K Talmoudi ◽  
A Bahrini ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Vaccination Coverage ◽  
Vaccine Effectiveness ◽  
Coverage Rate ◽  
Hbv Infection ◽  
Hepatitis B Vaccination ◽  
Reference Laboratory ◽  
Test Results ◽  
Vaccination Coverage Rate ◽  
The Impact

Abstract Introduction Vaccination against hepatitis B represents the most effective preventive measure to reduce the global impact of this infection. In Tunisia hepatitis B vaccination was introduced for health professionals in 1992 and for the general population in 1995. The objectives of this study were to evaluate the impact of vaccination twenty years after its introduction. Methods It was a descriptive study of data provided by the national survey of prevalence of Hepatitis B in Tunisia, which was a household-based study conducted in 2015. Blood samples sent to the reference laboratory to test markers of hepatitis B virus infection. The Vaccine effectiveness rate was calculated using the following formula: VE = 1 - Odds-ratio (OR), where OR = ratio of odds of being vaccinated among subjects with positive HBsAg test results to the odds of being vaccinated among subjects with negative HBsAg test results. Results Approximately a quarter of our population reported having been vaccinated against HBV, a coverage rate of 26.9%. Among subjects above 20 years of age, this rate was 85.3%. Besides, 83.7% of vaccinated subjects had received the three required doses of the HBV vaccine. Analysis of vaccination status by great regions of the country showed that the vaccination coverage rate was higher in the southern region. Regarding HBsAg prevalence, the rate was significantly higher among unvaccinated subjects 0.3% vs 2.2% in those vaccinated (OR = 0.11 [0.07-0.18]). We found that among vaccinated subjects, the serologic response rate at vaccination was only 63.2% which represented 16.2% of the total population. The vaccine effectiveness indicated that vaccination reduced by 88.6% the risk of HBV infection. Conclusions These results demonstrate that vaccination against hepatitis B introduced in the national immunization schedule since 1995 has reduced the infection although the vaccination coverage rate remains below 90%. Key messages Importance of vaccination that reduced by 88.6% the risk of HBV infection. More effort required to raise awareness about vaccination against HBV.

MODELING THE IMPACT OF AWARENESS CREATED BY MEDIA CAMPAIGNS ON VACCINATION COVERAGE IN A VARIABLE POPULATION

2014 ◽  
Vol 22 (02) ◽  
pp. 249-270 ◽  
Author(s):  
ANUPAMA SHARMA ◽  
A. K. MISRA
Keyword(s):  
Hepatitis B ◽  
Vaccination Coverage ◽  
Total Population ◽  
Hepatitis B Vaccination ◽  
Preventive Strategy ◽  
Successful Implementation ◽  
Global Public Health ◽  
Media Campaigns ◽  
Model Stability ◽  
The Impact

Vaccines are a core component of any preventive strategy designed to ensure the global public health. A major factor influencing the successful implementation of any immunization program is awareness and public acceptance of the vaccine. The present study focuses on potential impacts of awareness created by media campaigns on vaccination coverage of hepatitis B. In this paper, a SIR model with vital dynamics in a population of varying size is investigated, which couples hepatitis B vaccination and awareness created by media within a single framework. It is assumed that media campaigns propagate awareness about measures requisite for escaping the chances of contracting hepatitis B. The awareness created by media motivates people to get vaccinated and attain full immunization against hepatitis B virus. For analyzing the model, stability theory of differential equations is employed. First, equilibria of the system comprising fractions of the population are obtained and their stability behavior is discussed. Then the asymptotic behavior of total population is discussed in detail. Three threshold parameters R0, R1and R2governing the dynamics of infection and total population are also affirmed. The findings of numerical simulations are also in line with analytically obtained results.

Hepatitis B Seroepidemiology in Australia, One Decade After Universal Vaccination of Infants and Adolescents

2020 ◽  
Vol 20 (3) ◽  
pp. 341-347
Author(s):  
Xinting Lu ◽  
Helen E. Quinn ◽  
Rob I. Menzies ◽  
Linda Hueston ◽  
Lyn Gilbert ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Hepatitis B Surface Antigen ◽  
Age Groups ◽  
Baseline Period ◽  
Hbv Infection ◽  
Vaccine Uptake ◽  
Hepatitis B Vaccination ◽  
Vaccination Programs ◽  
Adolescent Vaccination ◽  
The Impact

Background: This study assessed the impact of the staged introduction of universal infant and adolescent catch-up hepatitis B vaccination programs on the prevalence of immunity and past hepatitis B virus (HBV) infection in targeted cohorts over almost a decade in Australia. Methods: We compared the prevalence of immunity in relevant cohorts of children and adolescents in repeated national serological surveys conducted in 1998-99, 2002 and 2007. Residual sera (n =2210) collected opportunistically from Australian laboratories in 2007 were tested for antibody to hepatitis B surface antigen (anti-HBs) indicating vaccine-induced immunity; sera from individuals aged 12-29 years with anti-HBs detected (n =386) were then tested for hepatitis B core antibody (anti-HBc) to identify past hepatitis B infection. Results: In 2007, compared with the baseline period of 1998-99, anti-HBs prevalence had increased significantly in all age groups below 24 years, by more than double in target children. Prevalence of anti-HBc was zero in the 12-14 years and reduced by 71% in those aged 15-19 years. The hepatitis B vaccination protected a significant number of targeted adolescents with a modest vaccine uptake (57% to 60% nationally). Conclusion: In a setting without incentives or school entry requirements, adolescent vaccination coverage was significantly higher when delivered by school-based rather than GP-based mechanisms. A cohort of children was growing up in Australia with a high prevalence of vaccineinduced immunity against hepatitis B, providing the best opportunity for controlling HBV infection in Australia.

scholarly journals Immune Status of Cohort of Children Vaccinated against Hepatitis B Virus in Ekiti State over Ten Years after Incorporation into National Program on Immunization

2019 ◽  
pp. 1-8
Author(s):  
A. O. Ajayi ◽  
E. E. Emmanuel ◽  
I. O. Oluwayemi ◽  
A. Olu-Taiwo ◽  
M. S. Odimayo
Keyword(s):  
Hepatitis B ◽  
Seroconversion Rate ◽  
Sampling Technique ◽  
Objective Evaluation ◽  
Hbv Infection ◽  
Hepatitis B Vaccination ◽  
Cross Sectional ◽  
Female Ratio ◽  
Hbv Vaccination ◽  
The Impact

Background: Hepatitis B vaccine has been introduced in Nigeria for over a decade now, yet, data on sero-conversion status of the immunized cohort in the population are scarce. Such data are important for objective evaluation of the impact and effectiveness of the HBV vaccination program. This study therefore aims at determining the sero-conversion status and the prevalence of HBV infection among immunized cohort of children in Ekiti state, Nigeria. Methodology: This cross-sectional study was conducted across the three senatorial districts of Ekiti state, between October and December, 2017. A total of 441 children consisting of 226 males and 215 females (Male to female ratio= 1.1:1). Immunization was confirmed by immunization cards. Multistage sampling technique was used. Questionaire were administered after caregiver’s consent and assent from subjects, 2 to 5 mls of blood samples were then collected and tested for the various hepatitis B viral markers (HBeAg, HBeAb, HBcAb, HBsAb and HBsAg) using Hepatitis B combo kit manufactured by Innovita Biological Technology. Very low levels antibody titres which may not be detectable by qualitative detection method used is a limitation to this study. Results: Subjects were between 5 to 10 years. All subjects had 3 full doses of hepatitis B vaccination before the age of 1 year and all subjects were negative for HBsAg, HBeAg, HBeAB and HBcAb. However, only 47 (10.7%) had detectable HBsAb. Among HBsAb positive patients 22 were males while 25 were females. Our findings showed zero prevalence of hepatitis B but minimal seroconversion rate among vaccinated children in Ekiti state, Nigeria. Conclusion: Hepatitis B vaccination protects children against HBV in the study population. However, seroconversion rate showed that majority of the children may be at risk of HBV infection at a later age. We recommend a booster dose of HBV vaccination.

scholarly journals Modelling alternative strategies for delivering hepatitis B vaccine in prisons: the impact on the vaccination coverage of the injecting drug user population

2008 ◽  
Vol 136 (12) ◽  
pp. 1644-1649 ◽  
Author(s):  
A. J. SUTTON ◽  
N. J. GAY ◽  
W. J. EDMUNDS ◽  
O. N. GILL
Keyword(s):  
Hepatitis B ◽  
Drug User ◽  
Vaccination Coverage ◽  
Hepatitis B Vaccine ◽  
Entire Population ◽  
Hepatitis B Vaccination ◽  
Alternative Strategies ◽  
England And Wales ◽  
The Impact ◽  
Injecting Drug User

SUMMARYSince 2001 hepatitis B vaccination has been offered to prisoners on reception into prisons in England and Wales. However, short campaigns of vaccinating the entire population of individual prisons have achieved high vaccination coverage for limited periods, suggesting that short campaigns may be a preferable way of vaccinating prisoners. A model is used that describes the flow of prisoners through prisons stratified by injecting status to compare a range of vaccination scenarios that describe vaccination on prison reception or via regular short campaigns. Model results suggest that vaccinating on prison reception can capture a greater proportion of the injecting drug user (IDU) population than the comparable campaign scenarios (63% vs. 55·6% respectively). Vaccination on prison reception is also more efficient at capturing IDUs for vaccination than vaccination via a campaign, although vaccination via campaigns may have a role with some infections for overall control.

scholarly journals Hepatitis B vaccination coverage rate and immune response among primary health care workers in Sarajevo Canton, Bosnia and Herzegovina

2020 ◽  
Vol 0 (0) ◽  
pp. 0-0
Author(s):  
Sabina Šegalo ◽  
Emina Kiseljaković ◽  
Lejla Berhamović ◽  
Arzija Pašalić ◽  
Sabina Mahmutović Vranić ◽  
...  
Keyword(s):  
Health Care ◽  
Immune Response ◽  
Primary Health Care ◽  
Hepatitis B ◽  
Vaccination Coverage ◽  
Health Care Workers ◽  
Hepatitis B Vaccination ◽  
Vaccination Coverage Rate ◽  
Primary Health ◽  
Care Workers

scholarly journals 1066. Immune Escape Mutant Detection Using Commercially Available Methods for Hepatitis B Surface Antigen Serological Testing

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S562-S562
Author(s):  
Robert Gish ◽  
Vincent Streva
Keyword(s):  
Hepatitis B ◽  
Immune Escape ◽  
Hepatitis B Surface Antigen ◽  
Panel Member ◽  
The United States ◽  
Hbv Infection ◽  
Hepatitis B Vaccination ◽  
Review Panel ◽  
B Virus ◽  
Escape Mutants

Abstract Background Although overall infection rates of Hepatitis B virus (HBV) in the United States (US) remain stable, as many as 2.2 million persons are still chronically infected with Hepatitis B Virus (HBV)1. Persons who inject drugs (PWID) are at a higher risk of HBV infection and since 2009 three states (KY, TN, WV) have reported up to a 114% increase in cases of acute HBV infection due to higher infection rates among a non-Hispanic white populations (30–39 years), and injection drug users2. Hepatitis B vaccination is recommended as primary prevention for adults who are at increased risk for HBV infection, including PWID. However, data from the National Health Interview Survey indicate that hepatitis B vaccination coverage is low among adults in the general population3, and it is likely to be lower among injection drug users. Hepatitis B Surface Antigen (HBsAg) is the first serological marker to appear after HBV exposure and infection; this marker is included in the recommended panel for acute hepatitis diagnosis and accurate detection is necessary for early and accurate diagnosis. Serological testing challenges exist for HBsAg due to the high degree of genetic variability which can further be exacerbated by endogenous and exogenous pressures. The immuno-dominant region may have one or more mutations described as immune escape mutations which can decrease or abrogate HBsAg binding to antibodies used in immunoassays. Although the prevalence of these mutations is not well documented in the United States, international studies have shown that up to 79% of HBV-reactivated patients (vs 3.1% of control patients; p< 0.001) carry HBsAg mutations localized in immune-active HBsAg regions4. Methods A study was conducted using a panel of 10 unique recombinant HBsAg immune escape mutants. Panel members were tested by commercially available HBsAg serological immunoassays. Results It was found that although commercially available HBsAg immunoassays are the primary diagnostic tool for HBV diagnosis, not all HBsAg immune escape mutants are detected, with some method detecting as few as 5 out of 10 of these mutant samples. Figure 1 Conclusion Improvement is needed in commercially available methods for the accurate detection of HBsAg. Disclosures Robert Gish, MD, Abbott (Consultant)AbbVie (Consultant, Advisor or Review Panel member, Speaker’s Bureau)Access Biologicals (Consultant)Antios (Consultant)Arrowhead (Consultant)Bayer (Consultant, Speaker’s Bureau)Bristol Myers (Consultant, Speaker’s Bureau)Dova (Consultant, Speaker’s Bureau)Dynavax (Consultant)Eiger (Consultant, Advisor or Review Panel member)Eisai (Consultant, Speaker’s Bureau)Enyo (Consultant)eStudySite (Consultant, Advisor or Review Panel member)Exelixis (Consultant)Fujifilm/Wako (Consultant)Genentech (Consultant)Genlantis (Consultant)Gilead (Consultant, Advisor or Review Panel member, Speaker’s Bureau)GLG (Consultant)HepaTX (Consultant, Advisor or Review Panel member)HepQuant (Consultant, Advisor or Review Panel member)Intercept (Consultant, Speaker’s Bureau)Ionis (Consultant)Janssen (Consultant)Laboratory for Advanced Medicine (Consultant)Lilly (Consultant)Merck (Consultant)Salix (Consultant, Speaker’s Bureau)Shionogi (Consultant, Speaker’s Bureau)Viking (Consultant)

scholarly journals Hepatitis B Virus Infection in Pregnancy: Immunological Response, Natural Course and Pregnancy Outcomes

2021 ◽  
Vol 10 (13) ◽  
pp. 2926
Author(s):  
Sirinart Sirilert ◽  
Theera Tongsong
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Pregnancy Outcomes ◽  
Natural Course ◽  
Hbv Infection ◽  
Chronic Hbv Infection ◽  
B Virus ◽  
Chronic Hbv ◽  
Adverse Pregnancy ◽  
The Impact

This review aimed to provide an update on the impact of pregnancy on the natural course of hepatitis B virus (HBV) infection and also on the impact of HBV infection on adverse pregnancy outcomes, including mother-to-child transmission (MTCT). For the literature review, original research articles, review articles, and guidelines were narratively reviewed and comprehensively validated. The databases of PubMed, EMBASE, and CINAHL were carefully searched for articles in English on topics related to HBV infection, pregnancy, and vertical transmission from 1960 to May 2021. Immunological changes during pregnancy such as suppression of Th1 response and induction of Th2 immunity lead to an impaired immune reaction to HBV and stimulate viral activity along with the reduction of CD8 T cells to escape immune detection. The impact of pregnancy on the natural course of chronic HBV infection seems to be minimal, while pregnancy can increase morbidity and mortality in the case of advanced HBV hepatitis or cirrhosis. Importantly, hepatitis flare or alanine aminotransferase (ALT) flare can occur during pregnancy and is more common during the postpartum period due to the interaction between HBV and the immune response. Interestingly, the impact of HBV infection on adverse pregnancy outcomes is more serious than ever thought. Updated evidence indicates that pregnancies with chronic HBV infection increase the risk of preterm birth and gestational diabetes, especially in cases of positive hepatitis e antigen (HBeAg).

scholarly journals Influenza Vaccination Campaign during the COVID-19 Pandemic: The Experience of a Research and Teaching Hospital in Milan

2021 ◽  
Vol 18 (11) ◽  
pp. 5874
Author(s):  
Pier Mario Perrone ◽  
Giacomo Biganzoli ◽  
Maurizio Lecce ◽  
Emanuela Maria Campagnoli ◽  
Ambra Castrofino ◽  
...  
Keyword(s):  
Influenza Vaccination ◽  
Teaching Hospital ◽  
Vaccination Coverage ◽  
Ad Hoc ◽  
Vaccination Campaign ◽  
Personal Data ◽  
Prevalence Ratio ◽  
Coverage Rate ◽  
Vaccination Coverage Rate ◽  
Research And Teaching

Background: During the COVID-19 pandemic, more than ever, optimal influenza vaccination coverage among healthcare workers (HCWs) is crucial to avoid absenteeism and disruption of health services, as well as in-hospital influenza outbreaks. The aim of this study is to analyze the 2020 influenza vaccination campaign, comparing it with the previous year’s in a research and teaching hospital in Northern Italy. Methods: adopting an approach based on combined strategies, three interventions were deployed: a promotional and educational campaign, vaccination delivery through both ad hoc and on-site ambulatories, and a gaming strategy. Personal data and professional categories were collected and analyzed using univariate logistic regression. Vaccinated HCWs were asked to fill in a questionnaire to describe their reasons for vaccination adherence. Results: the vaccination coverage rate (VCR) was 43.1%, compared to 21.5% in 2019. The highest increase was registered among administrative staff (308.3%), while physicians represent the most vaccinated category (n = 600). Moreover, residents (prevalence ratio (PR): 1.12; 95% CI 1.04–1.20), as well as intensive care (PR: 1.44; 95% CI: 1.24–1.69) and newborn workers (PR: 1.41; 95% CI: 1.20–1.65) were, respectively, the categories most frequently vaccinated for the first time. Conclusion: the significant increase in vaccination coverage rate confirms the suitability of the combined strategy of delivering the flu vaccination campaign and represents a first step towards reaching WHO recommended vaccination rates.

Increasing hepatitis B vaccination coverage of healthcare workers — global lessons for South Africa

2021 ◽  
Vol 71 ◽  
pp. 6-12
Author(s):  
Rosemary Joyce Burnett ◽  
Angela Dramowski ◽  
Edina Amponsah-Dacosta ◽  
Johanna Catharina Meyer
Keyword(s):  
South Africa ◽  
Hepatitis B ◽  
Vaccination Coverage ◽  
Healthcare Workers ◽  
Hepatitis B Vaccination
Sign in / Sign up

Export Citation Format

Share Document